IDEAYA Biosciences, Inc. IDYA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $157.52M+21.2% | $112.83M+33.7% | $298.93M-25.3% | $114.65M-37.4% | $130M+20.0% | ||
| $513.68M-8.7% | $526.56M-11.0% | $487.97M-6.1% | $555.09M+7.0% | $562.51M-4.7% | ||
| $696.11M-1.7% | $666.73M-3.3% | $802.66M-13.9% | $685.6M-3.9% | $707.87M-0.2% | ||
| $8.63M-2.7% | $8.22M-8.4% | $8.17M-0.8% | $8.82M+23.8% | $8.87M+28.4% | ||
| $1.03B-6.4% | $1.11B-1.3% | $1.19B-4.4% | $1.04B+6.9% | $1.1B+14.5% | ||
| $20.74M+17.6% | $17.58M+14.0% | $18.43M+46.7% | $17.27M+8.7% | $17.63M+180% | ||
| —— | —— | —— | —— | —— | ||
| $64.83M+27.5% | $58.82M+27.7% | $64.51M+58.7% | $55.34M+35.8% | $50.85M+104% | ||
| $93.08M+21.7% | $86.39M+33.0% | $93.1M+56.6% | $81.62M+94.3% | $76.51M+192% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K+12.5% | $9K+28.6% | ||
| -$835.08M-20.2% | -$736.54M-18.3% | -$653.27M-32.6% | -$772.51M-75.3% | -$695.02M-79.2% | ||
| $937.27M-8.5% | $1.02B-3.4% | $1.09B-7.5% | $959.65M+3.0% | $1.02B+9.5% | ||
| $1.03B-6.4% | $1.11B-1.3% | $1.19B-4.4% | $1.04B+6.9% | $1.1B+14.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are IDEAYA Biosciences, Inc.'s total assets?
- IDEAYA Biosciences, Inc. (IDYA) holds $1.0B in total assets, down 6.4% year over year.
- How much debt does IDEAYA Biosciences, Inc. have?
- IDEAYA Biosciences, Inc. carries $28.6M in total debt against $937.3M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does IDEAYA Biosciences, Inc. have?
- IDEAYA Biosciences, Inc. holds $157.5M in cash and equivalents.
- Can IDEAYA Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 10.74 — current assets exceed current liabilities.
- Where does IDEAYA Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
